Patent application number | Description | Published |
20080265069 | Milling Process - Process for milling a substance selected from sodium carbonate, sodium bicarbonate and sodium sesquicarbonate or trona, in which a cleaning agent is introduced into a mill for the purpose of obtaining a powder with a mean diameter of less than 100 μm and of inhibiting the formation of incrustations in the mill. | 10-30-2008 |
20100107638 | Device and process for distributing a fluid - Device for distributing a fluid in a controlled manner, in particular for distributing a gas loaded with particles, the device comprising a pipe ( | 05-06-2010 |
20110135553 | Milling process - Process for milling a substance selected from the group consisting of sodium carbonate, sodium bicarbonate, sodium sesquicarbonate, and trona, in which the substance is milled with a cleaning agent in a mill for the purpose of obtaining a powder with a mean diameter of less than 100 μm and of inhibiting the formation of incrustations in the mill. In a process for scrubbing a flue gas contaminated by a volatile acid compound, the powder is injected in the flue gas. | 06-09-2011 |
20140246522 | Device and process for distributing a fluid - A device for distributing a fluid in a controlled manner, in particular for distributing a gas loaded with particles, the device comprising a pipe ( | 09-04-2014 |
Patent application number | Description | Published |
20100099958 | Method of identifying when a patient undergoing hemodialysis is at increased risk of death - The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a substantial change in the rate of decline of at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data in deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a substantial change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients. | 04-22-2010 |
20110079558 | METHOD OF CONTROLLING DIFFUSIVE SODIUM TRANSPORT IN DIALYSIS - A method of controlling diffusive sodium transport from the dialysate solution to the blood of a patient undergoing hemodialysis treatment or from the blood to the dialysate solution includes calculating SNa | 04-07-2011 |
20110137136 | METHOD OF IDENTIFYING WHEN A PATIENT UNDERGOING HEMODIALYSIS IS AT INCREASED RISK OF DEATH - The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, including systolic blood pressure, serum albumin concentration level, body weight, body temperature, serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients. | 06-09-2011 |
20110237996 | Methods of Regional Citrate Anticoagulation Dialysis - A method of performing regional citrate anticoagulant dialysis of a patient's blood includes flowing blood from and back to the patient through an extracorporeal circuit including a dialyzer having semi-permeable dialysis membranes and a dialysate chamber surrounding the membranes. The method further includes flowing a dialysate containing calcium and citrate through the dialysate chamber of the dialyzer and introducing citrate into the patient's blood upstream of the dialyzer, whereby the patient's blood is dialyzed. The method can further include predicting the concentration of systemic ionized calcium in the blood of the patient at any point in the dialysis treatment or post-dialysis, such as by a mathematical model. The method can further include statistically correcting the preliminary predicted post-dialysis concentration of systemic ionized calcium in the patient's blood to provide a final predicted post-dialysis systemic ionized calcium concentration. The method can further include statistically correcting the preliminary predicted systemic ionized calcium concentration for any time point during the dialysis treatment to provide a final predicted systemic ionized calcium concentration for that time point. | 09-29-2011 |
20130041684 | System And Method Of Identifying When A Patient Undergoing Hemodialysis Is At Increased Risk Of Death By A Logistic Regression Model - Identifying a patient undergoing periodic hemodialysis treatments at increased risk of death by a logistic regression model includes selecting one or more clinical or biochemical parameter parameters associated with a probability of death of the patient while the patient is undergoing periodic hemodialysis treatments, and estimating the probability of death of the patient over a future time interval by a logistic regression model including model coefficients, the model coefficients determined by analyzing data from deceased patients that were previously undergoing periodic hemodialysis treatments, the analysis including a longitudinal analysis backwards in time on the one or more clinical or biochemical parameters of the deceased patients. The patient is identified as having an increased risk of death if the probability of death of the patient is greater than a predetermined threshold probability. | 02-14-2013 |
20130244263 | METHOD OF IDENTIFYING WHEN A PATIENT UNDERGOING HEMODIALYSIS IS AT INCREASED RISK OF DEATH - The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients. | 09-19-2013 |
20140128791 | System and Method of Modeling Erythropoiesis Including Iron Homeostasis - A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, the model including iron homeostasis, and employing the patient parameters and an initially selected ESA administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen. The method then includes administering ESA to the patient with an ESA administration regimen predicted to adjust the patient's hematocrit and/or hemoglobin concentration to the desired range at the predetermined time. The method can be implemented in a hemodialysis system. | 05-08-2014 |
20140200181 | SYSTEM AND METHOD OF MODELING ERYTHROPOIESIS AND ITS MANAGEMENT - A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, and employing the patient parameters and an initially selected EPO administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen. Optionally, if the patient's hematocrit and/or hemoglobin concentration is not predicted by the model to be in the desired range at the predetermined time, the method includes employing the model with one or more different ESA administration regimens until the model predicts that the patient's hematocrit and/or hemoglobin concentration will be in the desired range at the predetermined time. The method then includes administering ESA to the patient with an ESA administration regimen predicted to adjust the patient's hematocrit and/or hemoglobin concentration to the desired range at the predetermined time. The method can be implemented in a computer system for adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen. | 07-17-2014 |
20140353251 | Methods of Regional Citrate Anticoagulation Dialysis - A method of performing regional citrate anticoagulant dialysis of a patient's blood includes flowing blood from and back to the patient through an extracorporeal circuit including a dialyzer having semi-permeable dialysis membranes and a dialysate chamber surrounding the membranes. The method further includes flowing a dialysate containing calcium and citrate through the dialysate chamber of the dialyzer and introducing citrate into the patient's blood upstream of the dialyzer, whereby the patient's blood is dialyzed. The method can further include predicting the concentration of systemic ionized calcium in the blood of the patient at any point in the dialysis treatment or post-dialysis, such as by a mathematical model. The method can further include statistically correcting the preliminary predicted post-dialysis concentration of systemic ionized calcium in the patient's blood to provide a final predicted post-dialysis systemic ionized calcium concentration. The method can further include statistically correcting the preliminary predicted systemic ionized calcium concentration for any time point during the dialysis treatment to provide a final predicted systemic ionized calcium concentration for that time point. | 12-04-2014 |
20150208988 | DETECTING INDICATIONS OF INTRADIALYTIC MORBID EVENTS BY MEASUREMENT OF RELATIVE BLOOD VOLUME, BLOOD PRESSURE AND HEART RATE - A method of detecting an indication of a potential intradialytic morbid event (IME) by monitoring a patient's condition during excess fluid removalby ultrafiltration during a hemodialysis treatment includes determining the patient's relative blood volume (RBV), and removing a portion of the volume of excess fluid from blood of the patient at an initial ultrafiltration rate while periodically monitoring a second derivative over time of the relative blood volume (SDRBV). The method then includes continuing to remove excess fluid from blood of the patient at the same ultrafilration rate, or, optionally, incrementally increasing the ultrafiltration rate. The method further includes triggering an alarm for an IME for the patient if the SDRBV is in a range of between a low SDRBV alarm level and a high SDRBV alarm level, and, alternatively or additionally monitoring the patient's normalized blood pressure ratio, and taking a remedial action if the alarm is triggered. | 07-30-2015 |